Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery

Sponsor
City of Hope Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05203627
Collaborator
National Cancer Institute (NCI) (NIH)
60
1
2
35.6
1.7

Study Details

Study Description

Brief Summary

This clinical trial test whether taking part in a diet support intervention will help with patients nutrition and quality of life after surgery for esophagus or stomach cancer. The information learned by doing this research study may help patients get more information and/or support on eating after esophagus and stomach cancer surgery.

Condition or Disease Intervention/Treatment Phase
  • Other: Best Practice
  • Other: Questionnaire Administration
  • Other: Telemedicine Visit
N/A

Detailed Description

PRIMARY OBJECTIVES:
  1. Assess the feasibility, retention, and satisfaction of the Telehealth Intervention for Self-Management of Eating after Gastric Surgery (TIMES) intervention as measured by the percentage of patients who a) agree to participate; b) complete a majority of the intervention (at least 2 sessions); and c) report satisfaction with the intervention (through structured exit interviews).

  2. Assess the preliminary efficacy of TIMES for patient reported outcomes for quality of life (QOL), dietary symptoms, and self-management.

  3. Assess the preliminary efficacy of TIMES for objective measures of patient nutrition.

OUTLINE: Patients are randomized in to 1 of 2 arms.

ARM I: Patients receive 4 telehealth sessions over 1 hour each over 4 months. Patients also receive an intervention guidebook.

ARM II: Patients receive standard nutritional support.

After completion of study, patients are followed up for 6 months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Care Provider)
Primary Purpose:
Supportive Care
Official Title:
Telehealth Intervention for Self-Management of Dietary Quality of Life After Gastric Cancer Surgery
Actual Study Start Date :
Jan 21, 2020
Anticipated Primary Completion Date :
Jan 9, 2023
Anticipated Study Completion Date :
Jan 9, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm I (telehealth session, guidebook)

Patients receive 4 telehealth sessions over 1 hour each over 4 months. Patients also receive an intervention guidebook.

Other: Questionnaire Administration
Ancillary studies

Other: Telemedicine Visit
Receive telehealth sessions

Active Comparator: Arm II (standard nutritional support)

Patients receive standard nutritional support.

Other: Best Practice
Receive standard nutritional support
Other Names:
  • standard of care
  • standard therapy
  • Other: Questionnaire Administration
    Ancillary studies

    Outcome Measures

    Primary Outcome Measures

    1. Feasibility of the Telehealth Intervention - Percent Participation [Up to 6 months]

      Feasibility of the Telehealth Intervention for Self-Management of Eating after Gastric Surgery (TIMES) intervention will be measured by the percentage of patients who agree to participate.

    2. Feasibility of the Telehealth Intervention - Percent Completion [Up to 6 months]

      Feasibility of the Telehealth Intervention for Self-Management of Eating after Gastric Surgery (TIMES) intervention will be measured by the percentage of patients who completes two sessions.

    3. Retention of the TIMES intervention [Up to 6 months]

      Measured by the percentage of patients who complete a majority of the intervention (at least 2 sessions).

    4. Satisfaction of the TIMES intervention [Up to 6 months]

      Measured by the percentage of patients who report satisfaction with the intervention (through structured exit interviews). Satisfaction and engagement will be assessed through the exit interview via qualitative data, content analysis approach.

    5. Patient reported outcomes - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ30): [Up to 6 months]

      EORTC-QLQ30 will be assessed with a 30-item instrument for QOL assessment, with subscales/items for function, global health, general symptoms (fatigue, pain, nausea, and vomiting), and financial toxicity.

    6. Patient reported outcomes - EORTC-Oesophago-Gastric Cancer Module [Up to 6 months]

      (EORTC-OG25) will be assessed with a 25-item measure for esophagogastric cancer-specific symptoms and emotional well-being.

    7. Patient reported outcomes - Patient Activation Measure (PAM) [Up to 6 months]

      Patient Activation Measure (PAM) will be assessed by using a Guttman-like scale that reflects a patient's level of engagement and empowerment in their healthcare.

    8. Patient reported outcomes - General Self-Efficacy Scale [Up to 6 months]

      A General Self-Efficacy Scale developed by Jerusalem and colleagues contains 10 items that assess perceived confidence in self-management. Items are rated on a 4-point Likert scale.

    9. Patient reported outcomes - The Post-Gastrectomy Nutrition Questionnaire [Up to 6 months]

      The Post-Gastrectomy Nutrition Questionnaire is a tool developed by the investigators to assess patient knowledge about diet and nutrition after surgery for GE cancer. Each item addresses specific content discussed in the telehealth sessions to assess changes in knowledge. Scoring is based on the number of questions answered correctly.

    10. Objective measures of patient nutrition - Weight [Up to 6 months]

      Weight will be recorded at baseline and 6 months to examine the preliminary efficacy of the intervention on objective measures of patient nutrition. Weight will be measured by kg.

    11. Objective measures of patient nutrition - Body Mass Index (BMI) [Up to 6 months]

      Body Mass Index will be calculated and recorded by dividing weight in Kg by height in m^2 at baseline and 6 months to examine the preliminary efficacy of the intervention on objective measures of patient nutrition.

    12. Objective measures of patient nutrition - Albumin levels [Up to 6 months]

      Serum albumin levels collected as routine follow-up care will be recorded at baseline and 6 months to examine the preliminary efficacy of the intervention on objective measures of patient nutrition. Albumin level will be measured g/dl.

    13. Objective measures of patient nutrition - Skeletal mass Index [Up to 6 months]

      Sarcopenia/skeletal muscle mass will be calculated at baseline and 6 months through CT scans performed as part of routine follow-up for gastroesophageal cancer include cross-sectional images at the level of the third lumbar vertebra (L3). The cross-sectional area of skeletal muscle mass in this region has been found in multiple studies to correlate with total body skeletal muscle mass. Skeletal muscle mass will be quantified using well described techniques applying a predefined Hounsfield unit (HU) threshold of -25 to 150 HU for skeletal muscle mass. Muscle boundaries will be corrected manually when necessary to obtain cross-sectional areas (cm2) for skeletal muscle. Skeletal muscle index (SMI, cm2/m2) is defined as the cross-sectional area of muscle at the L3 level normalized for BMI.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • The ability to understand English or Spanish.

    • Undergone curative intent surgery for gastric or gastroesophageal (GE) junction cancer.

    • Began oral intake within the past month.

    • Aged 21 years and older.

    • Able to participate in telehealth sessions.

    • This study will be conducted in patients aged 21 years or older who have undergone curative intent surgery for gastric or GE junction cancer.

    • Age criterion for this trial is based on the National Institute of Health (NIH')s age criteria, which defines an adult as individuals aged 21 years and over. There are no restrictions related to performance status or life expectancy.

    • All subjects must have the ability to understand and the willingness to sign a written informed consent.

    Exclusion Criteria:
    • Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 City of Hope Comprehensive Cancer Center Duarte California United States 91010

    Sponsors and Collaborators

    • City of Hope Medical Center
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Jae Y Kim, City of Hope Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    City of Hope Medical Center
    ClinicalTrials.gov Identifier:
    NCT05203627
    Other Study ID Numbers:
    • 19220
    • NCI-2021-12909
    • 19220
    • P30CA033572
    First Posted:
    Jan 24, 2022
    Last Update Posted:
    Jan 24, 2022
    Last Verified:
    Jan 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 24, 2022